Aurobindo Pharma Shares Tumble Almost 5% on Reports of Zentiva Acquisition Bid; Company Issues Clarification

CPA: EU Must Reject Aurobindo’s $5.5 Billion Zentiva Takeover - Coalition For A Prosperous America

Deal Would Entrench CCP-Controlled Supply Chains, Undermine European & U.S. Drug Security WASHINGTON, D.C. — The Coalition for a Prosperous America (CPA) today warned that Aurobindo Pharma’s proposed $5.5 billion acquisition of Prague-based Zentiva poses an unacceptable risk to Europe’s and America’s pharmaceutical security. CPA is calling on the European Union (EU), including Czech authorities and Eur…

Aurobindo Pharma shares tumble almost 5% on reports of Zentiva acquisition bid; company issues clarification

Aurobindo Pharma shares fell nearly 5% to ₹1,039 amid reports it may acquire Zentiva for $5-5.5 billion. This would be the largest acquisition by an Indian pharma company, enhancing its European presence, though Aurobindo clarified no definitive agreement has been made yet.

Aurobindo Pharma frontrunner to secure $5.6bn deal for Advent Zentiva

India’s Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generics manufacturer Zentiva from Advent International in a deal valued at up to $5.5bn, in what would be one of the largest European healthcare exits of the year, according to a report by the Economic Times. Advent acquired Zentiva from Sanofi in 2018 for €1.9bn, subsequently expanding the platform through acquisitions and organic growth to become a major European …